Alcantara Monica, Ngo Mylan, de la Cruz James, Menon Deepak, Barnett-Tapia Carolina, Katzberg Hans, Bril Vera
Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University Health Network (UHN), Toronto, ON, Canada.
Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Front Neurol. 2022 Apr 26;13:872762. doi: 10.3389/fneur.2022.872762. eCollection 2022.
To investigate the contribution of duration and temporal dispersion (TD) of the distal compound muscle action potential (CMAP) in discriminating chronic inflammatory demyelinating polyneuropathy (CIDP) from diabetic sensorimotor polyneuropathy (DSP) and from CIDP+DSP.
We performed a retrospective review of patients diagnosed with CIDP, DSP and CIDP+DSP (responsive to immunotherapy) and examined differences in CMAP duration and TD at baseline.
We included 59 subjects: 17 CIDP, 21 DSP and 21 CIDP+DSP. Of these, 16 (94.1%) CIDP, 18 (85.7%) CIDP+DSP and 1 (4.7%) DSP fulfilled the 2010 EFNS/PNS criteria for definite CIDP. There was no difference in CMAP duration or TD in all nerves (compound outcome) or in individual motor nerves. Patients with CIDP/CIDP+DSP had more conduction blocks, slower conduction velocities and more prolonged F wave latencies than those with DSP.
Measures of CMAP duration and TD were not helpful in distinguishing CIDP, DSP or CIDP+DSP patients; however, parameters such as F-wave latencies, conduction blocks or the number of demyelinating parameters were useful in this separation.
There are no definite nerve conduction criteria to distinguish patients with CIDP+DSP from DSP alone. Further studies focusing on measures of demyelination may provide stronger evidence to guide treatment decisions in CIDP + DSP patients.
探讨远端复合肌肉动作电位(CMAP)的时限和时间离散度(TD)在鉴别慢性炎症性脱髓鞘性多发性神经病(CIDP)与糖尿病性感觉运动性多发性神经病(DSP)以及CIDP合并DSP中的作用。
我们对诊断为CIDP、DSP和CIDP合并DSP(对免疫治疗有反应)的患者进行了回顾性研究,并检查了基线时CMAP时限和TD的差异。
我们纳入了59名受试者:17例CIDP、21例DSP和21例CIDP合并DSP。其中,16例(94.1%)CIDP、18例(85.7%)CIDP合并DSP和1例(4.7%)DSP符合2010年欧洲神经病学学会/周围神经学会(EFNS/PNS)明确CIDP的标准。所有神经(复合结果)或单个运动神经的CMAP时限或TD均无差异。与DSP患者相比,CIDP/CIDP合并DSP患者有更多的传导阻滞、更低的传导速度和更长的F波潜伏期。
CMAP时限和TD测量无助于区分CIDP、DSP或CIDP合并DSP患者;然而,F波潜伏期、传导阻滞或脱髓鞘参数数量等参数在这种区分中是有用的。
目前尚无明确的神经传导标准来单独区分CIDP合并DSP患者与DSP患者。进一步聚焦于脱髓鞘测量的研究可能会提供更有力的证据来指导CIDP合并DSP患者的治疗决策。